Cempra, Inc. to Present at Jefferies 2013 Global Healthcare Conference
CHAPEL HILL, N.C., May 29, 2013
CHAPEL HILL, N.C., May 29, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP)
today announced that Prabhavathi Fernandes, Ph.D., president and chief
executive officer of Cempra, will present at the Jefferies 2013 Global
Healthcare Conference at 1 p.m. EDT, Wednesday, June 5, at the Grand Hyatt in
New York. Dr. Fernandes will discuss the company's two differentiated
antibiotics, solithromycin (CEM-101) for community-acquired bacterial
pneumonia and TAKSTA™ (CEM-102 or fusidic acid) for the chronic, oral
treatment of gram positive pathogens including methicillin-resistant S. aureus
(MRSA) in prosthetic joint infections.
A live webcast will be available on Cempra's website at www.cempra.com. The
presentation will be archived on the company's website and available for 90
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead product
candidates are currently in advanced clinical development. Solithromycin
(CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain
exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product
candidate currently in a Phase 2 clinical trial for prosthetic joint
infections. Both seek to address the need for new treatments targeting
drug-resistant bacterial infections in the hospital and in the community. The
company also intends to use its series of proprietary lead compounds from its
novel macrolide library for uses such as the treatment of chronic inflammatory
diseases, endocrine diseases and gastric motility disorders. Additional
information about Cempra can be found at www.cempra.com.
Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include, among others: the results
of studies of our product candidates conducted by others; the results, timing,
costs and regulatory review of our studies and clinical trials; our need to
obtain additional funding and our ability to obtain future funding on
acceptable terms; our anticipated capital expenditures and our estimates
regarding our capital requirements; our ability to obtain FDA approval of our
product candidates; the possible impairment of, or inability to obtain,
intellectual property rights and the costs of obtaining such rights from third
parties; our dependence on the success of solithromycin and Taksta; and
innovation by our competitors. The reader is referred to the documents that we
file from time to time with the Securities and Exchange Commission.
Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
Russo Partners LLC
SOURCE Cempra, Inc.
Press spacebar to pause and continue. Press esc to stop.